Glioblastoma multiforme (GBM) is one of the most formidable brain tumors with a mean survival period of approximately 12 months. To date, a combination of radiotherapy and chemotherapy with an oral alkylating agent, temozolomide (TMZ), has been used as first-line therapy for glioma. However, the efficacy of chemotherapy for treating GBM is very limited; this is partly because of the high activity levels of the DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) in tumor cells, which creates a resistant phenotype by blunting the therapeutic effect of alkylating agents. Thus, MGMT may be an important determinant of treatment failure and should be considered as a suitable target for intervention, in an effort to improve the therapeutic efficacy of TMZ. In this study, we showed that smallinterfering RNA (siRNA)-based downregulation of MGMT could enhance the chemosensitivity of malignant gliomas against TMZ. Notably, TMZ-resistant glioma-initiating cells with increased DNA repair and drug efflux capabilities could be efficiently transduced with MGMT-siRNA by using a novel liposome, LipoTrust. Accordingly, such transduced gliomainitiating cells could be sensitized to TMZ in both in vitro and in vivo tumor models. Taken together, this study provides an experimental basis for the clinical use of such therapeutic combinations.
Introduction
Glioblastoma multiforme (GBM) is the most lethal form of primary glioma, and the median survival time for patients with GBM is less than 12 months, despite the administration of various therapies, including surgical resection, radiotherapy and chemotherapy. 1 A combination of radiotherapy and chemotherapy with an oral alkylating agent, temozolomide (TMZ), has been used as first-line therapy for glioma. However, the efficacy of TMZ for treating GBM is often very limited because of inherent or acquired resistance. The main determinant of the resistance to alkylating agents is O 6 -methylguanine-DNA methyltransferase (MGMT); this enzyme directly and specifically eliminates the cytotoxic alkyl adducts formed at the O 6 position of guanine and (less frequently) at the O 4 position of thymine. 2, 3 Thus, the downregulation of MGMT may enhance the chemosensitivity of malignant gliomas to TMZ.
For many years, gliomas, including GBM, were considered to be heterogeneous bulk tumors composed of differentiated and undifferentiated cells with selfrenewal and partial differentiation capabilities. 4 Therefore, glioma treatment failure was attributed to certain undifferentiated tumor cells that were responsible for regrowth. Tumors have been reported to harbor small cell populations possessing growth-sustaining and tumorigenesis capacities. These cells, called cancer stem cells or cancer-initiating cells, have been identified in leukemia, multiple myeloma, breast cancer and glioma. In solid tumors, they show many properties of normal stem cells such as self-renewal and multi-potency, and can also initiate tumor formation. Glioma-initiating cells (GICs) also support the cancer stem cell paradigm. They express genes associated with neural stem cells and differentiate into phenotypically diverse populations, including neuronal, astrocytic and oligodendroglial cells. 5 Moreover, GICs have been reported to contribute to radioresistance and chemoresistance through a preferential checkpoint response and the overexpression of DNA repair genes. 6, 7 Indeed, we previously showed that compared with established glioma cell lines (for example, T98G), neurosphere-forming GICs expressed higher levels of MGMT, due to which these cells were far more resistant to TMZ. 8 Consequently, efforts to sensitize cancer stem-like cells to chemotherapy can be directed at inhibiting molecular pathways involved in stem cell regulation. In addition to the increased DNA repair capacity, cancer stem-like cells may contribute to cytotoxic drug resistance through the expression of proteins associated with drug efflux, such as ATP-binding cassette (ABC) transporters. Normal stem cells and small subpopulations of rat and human glioma cells with stem cell-like properties have previously been identified by their ability to expel the fluorescent dye Hoechst 33342, a compound known to be effluxed by ABC transporters. [9] [10] [11] Efflux properties, such as those of the ABC transporters, have been suggested to be significant in maintaining neural stem cells in an undifferentiated state, and in protecting them from toxic substances in vivo. Thus, it is crucial to develop a new strategy to target GBM stem cells having drug resistance capacity. Liposome-mediated delivery could bypass the ABC transporters and overcome the drug resistance conferred by these transporters.
In this study, we delivered small-interfering RNA (siRNA) for MGMT encapsulated in cationic liposomes. RNAi therapy requires the development of clinically appropriate, safe and effective drug delivery systems. To this end, we used a novel liposome (LipoTrust EX Oligo) as an in vivo delivery system; this liposome has recently been described as an efficient in vivo delivery system. 12 In this study, we aimed to examine whether siRNAbased downregulation of MGMT could enhance the chemosensitivity of GICs for TMZ, and to provide an experimental basis for the clinical use of such therapeutic combinations.
Results

MGMT-siRNAs suppress MGMT expression in glioma cell lines
We first elucidated the knockdown effects of three siRNAs for MGMT (types A, B and C). Two MGMTexpressing glioma cells, T98G and U251 nu/nu, were transduced with these siRNAs by using LipoTrust EX Oligo according to the instruction manual. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that all three MGMT-siRNA constructs could efficiently downregulate the expression of MGMT (Figure 1a) . We thus used mixed siRNA for further in vitro and in vivo experiments.
MGMT-siRNAs enhance the efficacy of TMZ in MGMT-expressing glioma cell lines
The glioma cells were treated with an MGMT-siRNA and LipoTrust complex before the addition of TMZ, and the viable cell numbers were measured by the WST assay. MGMT-negative U251SP cells were very sensitive to TMZ alone, and showed no additional toxicity with MGMT-siRNA. In contrast, TMZ alone reduced the number of T98G and U251 nu/nu cells by a mere 13 and 35%, respectively, compared with the dimethyl sulfoxide (DMSO) control. MGMT-siRNA alone showed minimal reduction in T98G cell growth. However, MGMT-siRNA in combination with TMZ induced dramatic cytotoxicity in both cell lines (Figure 1b) .
Efficient RNAi liposome-mediated delivery in GBM-initiating cells
We established tumor-initiating cell lines, also known as tumor stem cells, from tumor tissues obtained from GBM patients. Tumor stem cells possibly contain many similar properties to normal stem cells, which may confer a long life span, including relative quiescence, resistance to drugs and toxins through the expression of several ABC transporters, 13, 14 and an active capacity for DNA repair. 7 First, we investigated whether LipoTrust efficiently delivers siRNA to GICs that are known to express proteins that have a physiological role in the export of drugs. As shown in Figure 2a , almost all the GICs were successfully transfected with FAM-labeled siRNA by LipoTrust. Previous studies have reported that GICs express abundant levels of MGMT, which could help explain their tremendous capacity for DNA repair. 7, 8 The results of conventional RT-PCR as well as real-time PCR confirmed that the MGMT-siRNA/LipoTrust complex effectively downregulated MGMT expression in both GIC lines (Figure 2b ).
MGMT-siRNA enhances the efficacy of TMZ in GBM-initiating cells
Glioma-initiating cells were resistant to TMZ alone; this result is in agreement with that of a previous study. 8 MGMT-siRNA in combination with TMZ exerted the greatest antitumor effect. It should be noted that the most substantial cytotoxicity was observed in GICs treated with a combination of MGMT-siRNA and TMZ (Figure 2c ).
Liposome-mediated siRNA delivery in in vivo tumors
One of the limiting factors in the clinical use of siRNA technology is the delivery to target cells in vivo. We investigated whether intratumoral administration of siRNA/LipoTrust complex is efficient in delivering siRNA in subcutaneous glial tumors derived from GICs. First, we injected 80 pmol of an FAM-labeled siRNA/ LipoTrust complex intratumorally once a day for 5 days. FAM-siRNA was distributed diffusely within the tumor ( Figure 3a) . Next, the knockdown of MGMT expression was investigated by using an MGMT-siRNA/LipoTrust complex. MGMT was expressed in 99% of the tumor cells administered with control siRNA, compared with only 7% of cells in MGMT-siRNA-administered tumors ( Figure 3b ).
Treatment of subcutaneous tumor models with a combination of MGMT-siRNA and TMZ
Subcutaneous glial tumors in nude mice were treated with either TMZ alone, MGMT-siRNA alone or a combination of the two. Mice were separated into four groups (five animals each) (control group, TMZ group, siRNA group and TMZ plus siRNA group) when the diameter of the tumors reached 10 mm. The mice were given intratumoral injections of 80 pmol of siRNA complex or phosphate-buffered saline (PBS) followed by intraperitoneal (i.p.) injections of 50 mg kg À1 TMZ or DMSO once every day from days 1-5. The tumor growth was not affected in mice administered MGMT-siRNA alone. Mice that were administered TMZ alone showed slight tumor reduction, whereas those received the combination of TMZ and siRNA showed a significant Combination of MGMT-siRNA and TMZ in GBM stem cells T Kato et al decrease in tumor growth ( Figure 4 ). There was no difference in tumor size between mice that were intratumorally injected with siRNA and control mice that were intratumorally injected with PBS (data not shown).
Treatment of brain tumor models in NOD/SCID mice by a continuous drug delivery system
Intracranial inoculation of GICs can generate infiltrative tumors that phenocopy features of parental human GBM tumors, while glioma cell lines tend to form welldemarcated tumors in the brains of mice. 4, 5, 8 The brain tumor model generated from GICs is ideal to investigate the efficacy of our strategy.
We used an osmotic pump as the drug delivery system, which could supply the siRNA complex at a flow rate of 0.5 ml h À1 for a week. We transplanted 10 5 cells GICs in the right frontal lobe of NOD-SCID mice, and simultaneously implanted an osmotic pump containing the MGMT-siRNA/LipoTrust complex. TMZ was administered i.p. for 5 consecutive days starting from day 2. Although mice treated with TMZ alone showed longer survival than untreated mice, Kaplan-Meier analysis revealed that mice receiving MGMT-siRNA had a significantly better response to TMZ ( Figure 5 ). This result suggests that inhibiting MGMT expression using MGMT-siRNA sensitizes mice to TMZ treatment in the brain tumor model. This result is similar to that observed in subcutaneous tumor models. The glioma cells were treated with MGMT-siRNA and LipoTrust complex before the addition of TMZ, and the viable cell numbers were measured by the WST assay. MGMT-negative U251SP cells were very sensitive to TMZ alone, and showed no additional toxicity with MGMT-siRNA and TMZ. In contrast, TMZ alone reduced the number of T98G and U251 nu/nu cells by a mere 13 and 35%, respectively, compared with the dimethyl sulfoxide (DMSO) control. MGMT-siRNA alone showed minimal reduction in T98G cell growth, but MGMT-siRNA in combination with TMZ induced dramatic cytotoxicity in both cell lines. **Po0.01, *Po0.05 compared with control siRNA+DMSO.
Combination of MGMT-siRNA and TMZ in GBM stem cells T Kato et al
Discussion
The principal finding of this study is that liposomemediated in vivo delivery of MGMT-siRNA efficiently enhanced the cytotoxicity of TMZ in GICs. Notably, although glioma stem cells are considered to have extensive resistance to chemotherapeutic agents due to the high expression of DNA repair-related molecules, our study showed that liposomes were able to deliver the siRNA into glioma stem cells effectively, thus inducing susceptibility to TMZ.
Overcoming TMZ resistance due to MGMT
MGMT is capable of counteracting the cytotoxicity induced by O
6
-alkylating agents, and the increasing MGMT expression level correlates well with in vitro and in vivo glioma resistance to TMZ. [15] [16] [17] [18] However, in this process, MGMT is rapidly degraded through the ubiquitin/proteasome pathway after receiving alkyl groups from DNA, and the repletion of cellular MGMT pools depends on resynthesis of the molecule. 19 This makes it a suitable target for intervention in an effort to improve the therapeutic efficacy of TMZ. O
-Benzylguanine (O 6 -BG) is a potent inhibitor that irreversibly inactivates MGMT by covalent transfer of its benzyl group to the MGMT active site cysteine residues. 20 As a result, O
-BG enhances TMZ cytotoxicity in MGMT-proficient glioma cells both in vitro and in vivo, but not in MGMT-deficient cells. 21 Because patients with MGMT overexpression in the tumors respond more poorly to alkylating agents, co-administration of O 6 -BG to deplete the tumor pools of MGMT to enhance drug cytotoxicity has been previously attempted in clinical settings. 22, 23 However, systemic delivery of O 6 -BG increased the myelotoxicity caused by MGMT depletion in bone marrow cells, and therefore the dose of alkylating agents was reduced to a subtherapeutic level. Consequently, none of the patients responded to this drug combination. Therefore, the therapeutic potential of adding O 6 -BG to enhance TMZ cytotoxicity in tumor cells has thus far been discouraging. In this regard, intratumoral delivery of MGMT-siRNA may be more advantageous as compared to O 6 -BG. 
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Use of liposomes to deliver nucleic acids could be an efficient strategy in stem cells that have ABC transporters that render them drug resistant. Unilamellar and multilamellar liposomes are commonly used as pharmaceutical delivery vehicles. In an aqueous environment, one set of polar head groups can form the outer surface of the nanocomplex, whereas another set of polar head groups orients itself to face the interior hydrophilic core, which contains the nucleic acid payload. Liposomes have been used for the delivery of nucleic acids for more than 20 years: Felgner and co-workers 24, 25 detailed the ability of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N, N-trimethylammonium chloride to deliver both DNA and RNA into mammalian cell lines. The LipoTrust liposomes used in this study are cationic liposomes suitable for the in vivo delivery of siRNAs, antisense DNAs and microRNAs. Recently, Sato et al. 26 used vitamin-A-coupled LipoTrust liposomes to deliver antigp46 siRNA to fibrogenic hepatic cells for the treatment of liver cirrhosis. LipoTrust was introduced as an in vivo siRNA delivery agent in a recent review article. 12 Bypassing the ABC transporters on the cell surface, LipoTrust coupled with MGMT-siRNA can direct intracellular synthesis of the MGMT molecule.
Future directions and conclusions
Although liposomes are among the most popular nucleic acid delivery agents, there remain some concerns regarding their safety and delivery efficiency for therapeutic use. The toxicity of certain cationic lipid particles has been reported both in vitro and in vivo, and certain synthetic agents have been found to induce a gene signature of their own that might increase the off-target effects of the siRNA. In this study, LipoTrust itself showed in vitro cytotoxicity, but no remarkable toxicity was observed in vivo. A direct intracerebral approach called convection-enhanced delivery (CED) may be used as a strategy to address these issues. [27] [28] [29] CED uses a positive pressure generating a local pressure gradient to distribute agents in the extracellular space. Unlike diffusion delivery, CED is not significantly affected by the concentration, molecular weight or particle size of the agent. Further, CED ensures high concentrations and homogenous distribution of the drug throughout a given target tissue. Further studies should investigate the efficacy of the LipoTrust/MGMT-siRNA complex by the CED in a clinical setting.
Materials and methods
Glioma cell lines
The human glioma cell lines U251SP, T98G and U251 nu/nu were obtained from the Memorial Sloan-Kettering Cancer Institute (New York, NY, USA). They were maintained in Dulbecco's modified Eagle's medium (Gibco, Gaithersburg, MD, USA) containing 10% fetal bovine serum, 5 mM L-glutamine, 2 mM nonessential amino acids, and antibiotics (100 U ml À1 penicillin and 100 mg ml À1 streptomycin) at 37 1C in a humidified atmosphere with 5% CO 2 . TMZ was supplied by the Schering-Plough Research Institute (Kenilworth, NJ, USA). TMZ was dissolved in DMSO. Combination of MGMT-siRNA and TMZ in GBM stem cells T Kato et al
GBM-initiating cells
Glioblastoma-multiforme-initiating cells were established according to the protocol described previously. 8 Tissue collection. Tumor samples were obtained after consent from the patients (0222 and 0316); the procedure was approved by the Department of Neurosurgery, Nagoya University Hospital, Nagoya, Japan.
Primary sphere culture. Tumors were washed and acutely dissociated in PBS (pH 7.4) with 0.1% trypsin (Worthington Biochemical, Freehold, NJ, USA) and 0.04% DNaseI, type II (Sigma-Aldrich, St Louis, MO, USA). The cells were purified using a 70-mm cell strainer (BD Falcon, San Jose, CA, USA) followed by density-gradient centrifugation with Ficoll-Paque Premium (GE Healthcare, Waukesha, WI, USA). The purified cells were then cultured in a 100 Â 20 mm Petri dish (BD Falcon) in neurobasal medium (Invitrogen, Carlsbad, CA, USA) containing 2 mM L-glutamine, 0.5% N 2 supplement (Gibco), 1% B27 supplement (Gibco), 20 ng ml À1 recombinant human epidermal growth factor (rh-EGF; R&D Systems, Minneapolis, MN, USA), and 20 ng ml À1 rh-basic fibroblast growth factor (bFGF; R&D Systems) in 5% CO 2 at 37 1C.
Sphere formation. Approximately 2 weeks later, these cells became spherical, and the spherical cells that had been cultured for at least 2 months were defined as established GICs. Figure 4 Treatment of subcutaneous tumor models with a combination of MGMT-siRNA and TMZ. Subcutaneous glial tumors in nude mice were treated with either TMZ alone, MGMT-siRNA alone or a combination of the two. Mice were separated into four groups (control group, TMZ group, siRNA group and TMZ plus siRNA group) when the diameter of the tumors reached 10 mm. The mice were given intratumoral injections of 80 pmol of siRNA complex or PBS followed by intraperitoneal injections of 50 mg kg À1 TMZ or DMSO once every day from days 1 to 5. The tumor sizes were then measured using calipers two times every week. Tumor volume was calculated using the following formula: volume (mm 3 ) ¼ 0.5236 ddD, where D is the longest diameter and d the shortest diameter. The tumor growth did not decrease in mice administered MGMT-siRNA alone. Mice that were administered TMZ alone showed slight tumor reduction, whereas the combination of TMZ and siRNA was found to decrease tumor growth significantly. *Po0.05 compared with PBS+DMSO.
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Experimental procedure. One day before the experiments were performed, spherical GICs were dissociated using a NeuroCult chemical dissociation kit (StemCell Technologies, Vancouver, Canada).
Preparation of siRNAs
In this study, three siRNA formulations directed against MGMT (B-Bridge, catalog no, SYA21-325, name: 283SKSV_73, 283SKSV_284 and 283SKSV_481) were used. 
Formation of transfection complex
Small-interfering RNAs were transduced into glioma cells by using LipoTrust EX Oligo (Hokkaido System Science, Hokkaido, Japan). A vial of LipoTrust (1 mmol lipid) was reconstituted using 1 ml of nuclease-free water. For in vitro experiments, 10 ml of Opti-MEM (Gibco) containing 4 pmol siRNA was gently mixed with 0.5 ml of reconstituted LipoTrust solution (0.4 pmol siRNA/0.05 nmol lipid per ml; in vitro dose), and incubated for 20 min at room temperature. For animal experiments, 100 ml of Opti-MEM containing 80 pmol siRNA was gently mixed with 8 ml of reconstituted LipoTrust solution (0.8 pmol siRNA/0.08 nmol lipid per ml; in vivo dose). In a preliminary experiment, an in vivo dose of LipoTrust/MGMT-siRNA complex had a knockdown effect on MGMT after incubation for a week at 37 1C (data not shown).
Reverse transcriptase-polymerase chain reaction
We plated T98G and U251 nu/nu glioma cells in 100 ml Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at the density of 1 Â 10 3 cells per well in a 96-well plate. On day 1, the cells were transfected with the transfection complex described above. Total RNA was extracted from cells by using Trizol reagent (Invitrogen) on day 4. GICs (cultured from patients 0222 and 0316) were plated in 100 ml Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at the density of 8 Â 10 3 cells per well in a 96-well plate. Transfection of siRNAs and RNA extraction were performed on days 2 and 5, respectively. Total RNA (500 ng) was subjected to reverse transcription using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). The MGMT forward and reverse primer sequences were 5 0 -GCAATGAGAGGCAATCCT GT-3 0 and 5 0 -CAGTCCTCCGGAGTAGTTGC-3 0 , respectively. PCR was performed using GoTaq DNA Polymerase (Promega, Madison, WI, USA) with an initial denaturation step of 94 1C for 5 min; followed by 27 cycles of 94 1C for 30 s, 60 1C for 30 s and 72 1C for 30 s; and a final extension step at 72 1C for 7 min. Glyceraldehyde 3-phosphate dehydrogenase or Lamin A/C PCR products from the same RNA samples were amplified and used as internal controls. cDNA was quantified in a spectrophotometer and diluted to 500 ng ml À1 for use in quantitative real-time PCR. Realtime PCR was carried out using a LightCycler FastStart DNA Master PLUS SYBR Green I kit (Roche). The PCR reaction was analyzed with a Roche LightCycler. Lamin A/C was used as the internal control.
Cell viability assay
The relative cell numbers were determined using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan), a WST-8 cell proliferation assay system, according to the manufacturer's instructions. Glioma cell lines (T98G, U251 SP, and U251 nu/nu cells; 1 Â 10 3 cells per well), 0222-GICs and 0316-GICs (8 Â 10 3 cells per well) were added to wells containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum in a 96-well plate. The transfection complex was added to the glioma cell lines on day 1 and to the GIC culture on day 2. After 2 days, 100 mM TMZ or DMSO was added. We then assessed the viability of glioma cell lines 2 days later, and that of GICs, 8 days later.
Subcutaneous xenograft tumor model
The 0316-GIC cells (1 Â 10 5 cells) were transplanted subcutaneously in the right flank of BALB/c (nu/nu genotype) nude mice. The tumors were allowed to establish, and they were then passaged in vivo. When the subcutaneous tumors had reached a diameter of 
Intracranial xenograft tumor model
The 0316-GICs (1 Â 10 5 cells) were stereotactically injected into the frontal lobe of 6-week-old female NOD-SCID mice. The injection coordinates are as follows: 3 mm to the right of the midline, 2 mm anterior to the coronal suture and 3 mm in depth. Simultaneously, an Alzet osmotic pump (0.5 ml h À1 for 1 week; 1003D; Durect, Cupertino, CA, USA) containing 80 pmol siRNA complex (for in vivo use) was implanted. From day 2, 50 mg kg À1 of TMZ or DMSO was injected i.p. into the mice for 5 consecutive days. Survival analyses were performed using the Kaplan-Meier method.
Statistical analyses
The statistical significance of the observed difference was determined by analysis of variance (StatView software; SAS Institute, Cary, NC, USA), and subsequently, Bonferroni's correction for multiple comparisons was applied. Survival curves were generated using the Kaplan-Meier method. The log-rank statistic (StatView) was used to compare the distribution of the survival times. All reported P-values were two sided; a value less than 0.05 was considered to be statistically significant.
